{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"8.7","value":"7.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"}],"units":"Participants"}],"description":"Time from treatment initiation to disease progresion calculated using the method of Kaplan-Meier. RECIST v1.0 was used to evaluate response. Progression was defined as a 20% or greater increase in the sums of the longest dimensions of target lesions, or the appearance of new lesions within 8 weeks of study entry.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1, 8, and 15 for the first course and on days 1 and 15 for all subsequent courses. Patients also receive low-dose oral cyclophosphamide 50 mg/d on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nbevacizumab: Given IV\n\ncyclophosphamide: Given PO","id":"OG000","title":"Treatment (Bevacizumab, Cyclophosphamide)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Median Time to Progression","type":"PRIMARY","unitOfMeasure":"months"}